Luiza Cristine Diniz Neri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luiza Cristine Diniz Neri has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Maria Fernandes de Oliveira
Psychopharmacology Laboratory, Institute for Drug and Medicine Research, Federal University of Paraíba, João Pessoa 58051-900, PB, Brazil
2 shared publications - André Luiz Leocádio De Souza Matos2 shared publications
- Bárbara Fernandes Araújo Rodrigues2 shared publications
- Cícero Francisco Bezerra Felipe
Psychopharmacology Laboratory, Institute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, PB, Brazil
2 shared publications - Hugo Fernandes Oliveira Pires
Universidade Federal da Paraíba, Brazil
2 shared publications - Jéssica C. de Andrade
Psychopharmacology Laboratory, Institute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, PB, Brazil
2 shared publications
Latest Publications
- Open Access
- 25 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 27
Microglia-Targeted Nanotherapeutics in Major Depressive Disorder: An Integrative Perspective on Neuroinflammation and Drug Delivery
Major depressive disorder (MDD) is a highly prevalent psychiatric condition characterized by complex neurobiological mechanisms, including oxidative stress and neuroinflammation, with microglial activation playing a key role in its pathophysiology. Conventional antidepressants, though widely used, often fail to achieve remission due to limited efficacy, adverse effects, and poor patient adherence. In this context, nanotechnology-based drug delivery systems have emerged as promising strategies to overcome pharmacological limitations, enhance blood–brain barrier (BBB) penetration, and target neuroinflammatory pathways. This narrative review explores the role of microglia as both mediators of neuroinflammation and potential therapeutic targets in MDD. We examine different nanocarriers and their ability to modulate microglial activation, promote a shift from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype, and enhance antidepressant efficacy. Preclinical studies have demonstrated that nanoparticle-based systems not only improve drug bioavailability and brain targeting but also potentiate neuroprotective effects by reducing oxidative stress, promoting neurogenesis, and restoring synaptic plasticity. These findings highlight the potential of nanotechnology as a novel approach to precision neuropsychopharmacology. This review aims to provide an integrative perspective on how nanocarrier-based strategies targeting microglia could redefine future therapeutic paradigms for MDD.
- 25 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 27
Open AccessMicroglia-Targeted Nanotherapeutics in Major Depressive Disorder: An Integrative Perspective on Neuroinflammation and Drug Delivery
Major depressive disorder (MDD) is a highly prevalent psychiatric condition characterized by complex neurobiological mechanisms, including oxidative stress and neuroinflammation, with microglial activation playing a key role in its pathophysiology. Conventional antidepressants, though widely used, often fail to achieve remission due to limited efficacy, adverse effects, and poor patient adherence. In this context, nanotechnology-based drug delivery systems have emerged as promising strategies to overcome pharmacological limitations, enhance blood–brain barrier (BBB) penetration, and target neuroinflammatory pathways. This narrative review explores the role of microglia as both mediators of neuroinflammation and potential therapeutic targets in MDD. We examine different nanocarriers and their ability to modulate microglial activation, promote a shift from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype, and enhance antidepressant efficacy. Preclinical studies have demonstrated that nanoparticle-based systems not only improve drug bioavailability and brain targeting but also potentiate neuroprotective effects by reducing oxidative stress, promoting neurogenesis, and restoring synaptic plasticity. These findings highlight the potential of nanotechnology as a novel approach to precision neuropsychopharmacology. This review aims to provide an integrative perspective on how nanocarrier-based strategies targeting microglia could redefine future therapeutic paradigms for MDD.
- Open Access
- 28 July 2025
- Published by MDPI AG in Preprints.org
Targeting Microglia Via Nanotechnology: A Novel Strategy to Overcome Neuroinflammation in Major Depressive Disorder
Major Depressive Disorder (MDD) is a highly prevalent psychiatric condition characterized by complex neurobiological mechanisms, including oxidative stress and neuroinflammation, with microglial activation playing a key role in its pathophysiology. Conventional antidepressants, though widely used, often fail to achieve remission due to limited efficacy, adverse effects, and poor patient adherence. In this context, nanotechnology-based drug delivery systems have emerged as promising strategies to overcome pharmacological limitations, enhance blood–brain barrier penetration, and target neuroinflammatory pathways. This narrative review explores the role of microglia as both mediators of neuroinflammation and potential therapeutic targets in MDD. We examine different nanocarriers — such as polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers, magnetic nanoparticles, and liposomes — and their ability to modulate microglial activation, promote a shift from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype, and enhance antidepressant efficacy. Preclinical studies have demonstrated that nanoparticle-based systems not only improve drug bioavailability and brain targeting but also potentiate neuroprotective effects by reducing oxidative stress, promoting neurogenesis, and restoring synaptic plasticity. These findings highlight the potential of nanotechnology as a novel approach to precision neuropsychopharmacology. This review aims to provide an integrative perspective on how nanocarrier-based strategies targeting microglia could redefine future therapeutic paradigms for MDD.
- 28 July 2025
- Published by MDPI AG in Preprints.org
Open AccessTargeting Microglia Via Nanotechnology: A Novel Strategy to Overcome Neuroinflammation in Major Depressive Disorder
Major Depressive Disorder (MDD) is a highly prevalent psychiatric condition characterized by complex neurobiological mechanisms, including oxidative stress and neuroinflammation, with microglial activation playing a key role in its pathophysiology. Conventional antidepressants, though widely used, often fail to achieve remission due to limited efficacy, adverse effects, and poor patient adherence. In this context, nanotechnology-based drug delivery systems have emerged as promising strategies to overcome pharmacological limitations, enhance blood–brain barrier penetration, and target neuroinflammatory pathways. This narrative review explores the role of microglia as both mediators of neuroinflammation and potential therapeutic targets in MDD. We examine different nanocarriers — such as polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers, magnetic nanoparticles, and liposomes — and their ability to modulate microglial activation, promote a shift from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype, and enhance antidepressant efficacy. Preclinical studies have demonstrated that nanoparticle-based systems not only improve drug bioavailability and brain targeting but also potentiate neuroprotective effects by reducing oxidative stress, promoting neurogenesis, and restoring synaptic plasticity. These findings highlight the potential of nanotechnology as a novel approach to precision neuropsychopharmacology. This review aims to provide an integrative perspective on how nanocarrier-based strategies targeting microglia could redefine future therapeutic paradigms for MDD.
- Open Access
- 1 January 2024
- Published by Supervisão Clínica
The Role of the Clinical Pharmacist in the Implementation of Antimicrobial Stewardship Programs
Book Brazil in Advancing Pharmacotherapy and Clinical Pharmacy in Latin America Proceedings of the Fourth Brazilian Congress of Pharmacotherapy and Clinical Pharmacy doi: 10.62922/4cbffc ISBN: 978-65-983944-2-4 Editors Wallace Entringer Bottacin – ORCID | Lattes | Google Scholar Thaís Teles de Souza – ORCID | Lattes Walleri Christini Torelli Reis – ORCID | Lattes | Google […]
- 1 January 2024
- Published by Supervisão Clínica
Open AccessThe Role of the Clinical Pharmacist in the Implementation of Antimicrobial Stewardship Programs
Book Brazil in Advancing Pharmacotherapy and Clinical Pharmacy in Latin America Proceedings of the Fourth Brazilian Congress of Pharmacotherapy and Clinical Pharmacy doi: 10.62922/4cbffc ISBN: 978-65-983944-2-4 Editors Wallace Entringer Bottacin – ORCID | Lattes | Google Scholar Thaís Teles de Souza – ORCID | Lattes Walleri Christini Torelli Reis – ORCID | Lattes | Google […]
- Open Access
- 1 January 2024
- Published by Supervisão Clínica
Clinical Pharmacist's Role in Managing Patients with Chronic Kidney Disease: a Review
Book Brazil in Advancing Pharmacotherapy and Clinical Pharmacy in Latin America Proceedings of the Fourth Brazilian Congress of Pharmacotherapy and Clinical Pharmacy doi: 10.62922/4cbffc ISBN: 978-65-983944-2-4 Editors Wallace Entringer Bottacin – ORCID | Lattes | Google Scholar Thaís Teles de Souza – ORCID | Lattes Walleri Christini Torelli Reis – ORCID | Lattes | Google […]
- 1 January 2024
- Published by Supervisão Clínica
Open AccessClinical Pharmacist's Role in Managing Patients with Chronic Kidney Disease: a Review
Book Brazil in Advancing Pharmacotherapy and Clinical Pharmacy in Latin America Proceedings of the Fourth Brazilian Congress of Pharmacotherapy and Clinical Pharmacy doi: 10.62922/4cbffc ISBN: 978-65-983944-2-4 Editors Wallace Entringer Bottacin – ORCID | Lattes | Google Scholar Thaís Teles de Souza – ORCID | Lattes Walleri Christini Torelli Reis – ORCID | Lattes | Google […]